Edgewise Therapeutics (EWTX) Other Non Operating Income (2020 - 2026)

Edgewise Therapeutics (EWTX) has 7 years of Other Non Operating Income data on file, last reported at $5.1 million in Q1 2026.

• For the quarter ending Q1 2026, Other Non Operating Income fell 1.14% year-over-year to $5.1 million; the trailing twelve-month figure through Mar 2026 stood at $23.6 million (down 1.67% YoY), and the FY2025 full-year result was $23.6 million, down 5.63% from the prior year.
• Other Non Operating Income retreated to $5.1 million in Q1 2026, from $5.8 million in the prior quarter.
• In the past five years, Other Non Operating Income ranged from a high of $6.6 million in Q2 2024 to a low of $166000.0 in Q1 2022.
• A 5-year average of $4.2 million and a median of $5.1 million in 2026 frame the typical range for Other Non Operating Income.
• Across the five-year window, Other Non Operating Income surged 2014.29% in 2022 and slipped 17.13% in 2025, its largest moves.
• Tracing EWTX's Other Non Operating Income over 5 years: stood at $2.7 million in 2022, then jumped by 39.6% to $3.7 million in 2023, then jumped by 58.05% to $5.9 million in 2024, then declined by 1.96% to $5.8 million in 2025, then fell by 11.47% to $5.1 million in 2026.
• Business Quant data shows EWTX's Other Non Operating Income at $5.1 million in Q1 2026, $5.8 million in Q4 2025, and $6.2 million in Q3 2025.